Company:  EXELIXIS, INC. (EXEL)
Form Type:  4
Filing Date:  6/19/2019 
CIK:  0000939767 
Address:  1851 HARBOR BAY PARKWAY 
City, State, Zip:  ALAMEDA, California 94502 
Telephone:  (650) 837-7000 
Fiscal Year:  01/03 
Last Trade
Last Trade: 
$21.27  
Change: 
-0.86 (-3.89%)  
Trade Time: 
Jul 19  
Market Cap: 
$6.42B
Trade EXEL now with

© 2019  
Description of Business
Item 1. Business Overview Exelixis, Inc. ("Exelixis," "we," "our" or "us") is a biotechnology company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Since our founding in 1994, three products discovered at Exelixis have progressed through clinical development, received regulatory approval, and entered the marketplace. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET: CABOMETYX® (cabozantinib) tablets approved for advanced renal cell carcinoma, or RCC, and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer, or MTC. The third product, COTELLIC® (cobimetinib) tablets, is a formulation of cobimetinib and is an inhibitor of MEK, marketed under a collaboration with Genentech, Inc.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES